1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. ...
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. ...
1. From this systematic review and meta-analysis, use of erythropoietin-stimulating agents (ESAs) to achieve high hemoglobin targets in patients with ...
1. Preterm infants receiving erythropoiesis-stimulating agents (ESAs) performed better than placebo-receiving babies on cognitive tests assessing full-scale intelligence quotient (IQ), ...
